JP2003509467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003509467A5 JP2003509467A5 JP2001524618A JP2001524618A JP2003509467A5 JP 2003509467 A5 JP2003509467 A5 JP 2003509467A5 JP 2001524618 A JP2001524618 A JP 2001524618A JP 2001524618 A JP2001524618 A JP 2001524618A JP 2003509467 A5 JP2003509467 A5 JP 2003509467A5
- Authority
- JP
- Japan
- Prior art keywords
- lhrh antagonist
- administered
- short
- active agents
- lhrh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 71
- 239000002474 gonadorelin antagonist Substances 0.000 description 69
- 239000013543 active substance Substances 0.000 description 19
- 238000009093 first-line therapy Methods 0.000 description 15
- 238000011419 induction treatment Methods 0.000 description 15
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 239000003098 androgen Substances 0.000 description 12
- 239000003435 antirheumatic agent Substances 0.000 description 12
- 239000003433 contraceptive agent Substances 0.000 description 12
- 229940127234 oral contraceptive Drugs 0.000 description 12
- 239000003539 oral contraceptive agent Substances 0.000 description 12
- 229960003604 testosterone Drugs 0.000 description 12
- 150000003515 testosterones Chemical class 0.000 description 12
- 206010065789 Fallopian tube obstruction Diseases 0.000 description 8
- 230000002254 contraceptive effect Effects 0.000 description 8
- 208000030843 hydrosalpinx Diseases 0.000 description 8
- 230000003637 steroidlike Effects 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 229940030486 androgens Drugs 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 208000000450 Pelvic Pain Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 3
- 108010023617 abarelix Proteins 0.000 description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 3
- 229960002184 abarelix Drugs 0.000 description 3
- 108010070670 antarelix Proteins 0.000 description 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 3
- 229960003230 cetrorelix Drugs 0.000 description 3
- 108700008462 cetrorelix Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000011599 ovarian follicle development Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229950011372 teverelix Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15547899P | 1999-09-23 | 1999-09-23 | |
| US60/155,478 | 1999-09-23 | ||
| PCT/EP2000/009212 WO2001021194A2 (en) | 1999-09-23 | 2000-09-20 | Method for the therapeutic management of endometriosis and fallopian tube obstruction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011227603A Division JP2012051920A (ja) | 1999-09-23 | 2011-10-17 | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003509467A JP2003509467A (ja) | 2003-03-11 |
| JP2003509467A5 true JP2003509467A5 (enExample) | 2007-11-08 |
Family
ID=22555601
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001524618A Withdrawn JP2003509467A (ja) | 1999-09-23 | 2000-09-20 | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療する方法 |
| JP2011227603A Pending JP2012051920A (ja) | 1999-09-23 | 2011-10-17 | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011227603A Pending JP2012051920A (ja) | 1999-09-23 | 2011-10-17 | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1214086A2 (enExample) |
| JP (2) | JP2003509467A (enExample) |
| KR (1) | KR100772852B1 (enExample) |
| CN (2) | CN1376070A (enExample) |
| AU (1) | AU769482B2 (enExample) |
| BG (1) | BG66128B1 (enExample) |
| BR (1) | BR0014198A (enExample) |
| CA (1) | CA2383510A1 (enExample) |
| HK (1) | HK1049117A1 (enExample) |
| HU (1) | HUP0202741A3 (enExample) |
| IL (1) | IL148185A0 (enExample) |
| MX (1) | MXPA02002436A (enExample) |
| NO (1) | NO331198B1 (enExample) |
| NZ (1) | NZ534836A (enExample) |
| PL (1) | PL201898B1 (enExample) |
| RU (1) | RU2255759C2 (enExample) |
| SK (1) | SK3752002A3 (enExample) |
| TR (1) | TR200200738T2 (enExample) |
| TW (1) | TWI267373B (enExample) |
| UA (1) | UA73956C2 (enExample) |
| WO (1) | WO2001021194A2 (enExample) |
| ZA (1) | ZA200201374B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10157628A1 (de) * | 2001-11-26 | 2003-06-12 | Zentaris Ag | Injektionslösung eines LHRH-Antagonisten |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| AU2009206212B2 (en) | 2008-01-24 | 2014-01-16 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Lytic domain fusion constructs and methods of making and using same |
| CA2750582A1 (en) * | 2009-01-22 | 2010-07-29 | Maatschap Interne Geneeskunde Rijnstate | Method for the prophylaxis or treatment of flushing |
| IL238323B2 (en) | 2012-10-30 | 2023-11-01 | Esperance Pharmaceuticals Inc | Antibody/drug conjugates and methods of use |
| EP3384930A1 (en) | 2013-03-15 | 2018-10-10 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| WO2019036713A1 (en) | 2017-08-18 | 2019-02-21 | Abbvie Inc. | SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS |
| AU2018317472A1 (en) | 2017-08-18 | 2020-03-05 | Abbvie Inc. | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
| AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5064939A (en) * | 1990-02-06 | 1991-11-12 | The Salk Institute For Biological Studies | Cyclic gnrh antagonists |
| SE9301606D0 (sv) * | 1993-05-07 | 1993-05-07 | Per-Christer Oden | Composition for the treatment of impaired hair growth |
| HU218910B (hu) * | 1994-07-22 | 2000-12-28 | Ortho Pharmaceutical Corporation | Gonadotrofin-felszabadító hormon antagonista-polipeptidek alkalmazása emlősben ivarmirigy-szteroid-függő állapotok gyógykezelésére szolgáló gyógyszerkészítmények előállítására |
| US5658884A (en) * | 1994-07-22 | 1997-08-19 | The Medical College Of Hampton Roads | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| DE19513662A1 (de) * | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| RU2108583C1 (ru) * | 1996-07-29 | 1998-04-10 | Николай Владимирович Рымашевский | Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом |
| WO1998009645A1 (en) * | 1996-09-04 | 1998-03-12 | Dott Research Laboratory | Peptide-containing drug compositions for oral administration |
| JP2002502426A (ja) * | 1997-06-05 | 2002-01-22 | メルク エンド カンパニー インコーポレーテッド | ゴナドトロピン放出ホルモンの拮抗薬 |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
-
2000
- 2000-09-20 SK SK375-2002A patent/SK3752002A3/sk not_active Application Discontinuation
- 2000-09-20 JP JP2001524618A patent/JP2003509467A/ja not_active Withdrawn
- 2000-09-20 MX MXPA02002436A patent/MXPA02002436A/es active IP Right Grant
- 2000-09-20 CN CN00813196A patent/CN1376070A/zh active Pending
- 2000-09-20 UA UA2002043346A patent/UA73956C2/uk unknown
- 2000-09-20 RU RU2002111000/14A patent/RU2255759C2/ru not_active IP Right Cessation
- 2000-09-20 EP EP00967722A patent/EP1214086A2/en not_active Withdrawn
- 2000-09-20 TR TR2002/00738T patent/TR200200738T2/xx unknown
- 2000-09-20 CA CA002383510A patent/CA2383510A1/en not_active Abandoned
- 2000-09-20 WO PCT/EP2000/009212 patent/WO2001021194A2/en not_active Ceased
- 2000-09-20 HU HU0202741A patent/HUP0202741A3/hu unknown
- 2000-09-20 IL IL14818500A patent/IL148185A0/xx not_active IP Right Cessation
- 2000-09-20 BR BR0014198-4A patent/BR0014198A/pt not_active Application Discontinuation
- 2000-09-20 KR KR1020027003740A patent/KR100772852B1/ko not_active Expired - Fee Related
- 2000-09-20 NZ NZ534836A patent/NZ534836A/en not_active IP Right Cessation
- 2000-09-20 CN CNA2007100789192A patent/CN101045155A/zh active Pending
- 2000-09-20 AU AU77792/00A patent/AU769482B2/en not_active Ceased
- 2000-09-20 PL PL353244A patent/PL201898B1/pl not_active IP Right Cessation
- 2000-09-20 HK HK03101215.4A patent/HK1049117A1/zh unknown
- 2000-09-22 TW TW089119671A patent/TWI267373B/zh not_active IP Right Cessation
-
2002
- 2002-02-19 ZA ZA200201374A patent/ZA200201374B/en unknown
- 2002-03-21 NO NO20021430A patent/NO331198B1/no not_active IP Right Cessation
- 2002-04-05 BG BG106584A patent/BG66128B1/bg unknown
-
2011
- 2011-10-17 JP JP2011227603A patent/JP2012051920A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6569866B2 (en) | Sustained-release nalmefene preparations and method | |
| ES2435722T3 (es) | Noribogaína en el tratamiento del dolor y de la adicción a drogas | |
| JP5023315B2 (ja) | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| RU99117926A (ru) | Лекарственные формы и способ лечения расстройства мужской эректильной функции | |
| JP2007507538A5 (enExample) | ||
| CN1144486A (zh) | 卵巢雌激素依赖性病症的治疗 | |
| EP1275381A4 (en) | SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION | |
| Werthman et al. | MUSE therapy: preliminary clinical observations | |
| JP2003509467A5 (enExample) | ||
| JP2012051920A (ja) | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用 | |
| US5187177A (en) | Method and a pharmaceutical preparation for treating pain | |
| JP2004537500A5 (enExample) | ||
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| RU2002111000A (ru) | Способ терапевтического лечения внематочной пролиферации эндометриальной ткани, хронической боли в области таза и непроходимости фаллопиевых труб, фармацевтическая композиция и анатагонист LHRH-лекарственное средство для указанного лечения (варианты) | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| RU2002122084A (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств | |
| WO2003079976A3 (en) | A substance with sedative effect | |
| JP2002540148A5 (enExample) | ||
| RU2005135649A (ru) | Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| US10736874B1 (en) | Methods for treating pain associated with sickle cell disease | |
| CA2431125C (en) | A method for treating erectile dysfunction | |
| CZ20031727A3 (cs) | Nové terapeutické použití derivátu thienylcyklohexylaminu | |
| RU2001128509A (ru) | Способ лечения нейродегенерации |